Atorvastatin Calcium in Preventing Metabolic Syndrome in Patients With Prostate Cancer Receiving Long-Term Androgen-Deprivation Therapy

This study has been withdrawn prior to enrollment.
(Other more favorable treatments are now available.)
Sponsor:
Collaborator:
Information provided by (Responsible Party):
University of Nebraska
ClinicalTrials.gov Identifier:
NCT01555632
First received: February 9, 2012
Last updated: June 17, 2013
Last verified: June 2013
  Purpose

This randomized pilot clinical trial studies atorvastatin calcium in preventing metabolic syndrome in patients with prostate cancer receiving long-term androgen-deprivation therapy. Atorvastatin calcium may help prevent or reduce metabolic syndrome caused by long-term androgen-deprivation therapy


Condition Intervention
Recurrent Prostate Cancer
Stage I Prostate Cancer
Stage IIA Prostate Cancer
Stage IIB Prostate Cancer
Stage III Prostate Cancer
Stage IV Prostate Cancer
Drug: atorvastatin calcium
Drug: placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Pilot Study of Atorvastatin on Prevention of Metabolic Syndrome in Subjects With Prostate Cancer on Long Term Androgen-deprivation Therapy

Resource links provided by NLM:


Further study details as provided by University of Nebraska:

Primary Outcome Measures:
  • Overall change of metabolic syndrome score (divided into 6 groups according to the number of constituents [0-5] of metabolic syndrome) [ Time Frame: At 6 months ] [ Designated as safety issue: No ]
    A total of 60 subjects will yield 80% power at the 0.05 two-sided level of significance to detect 3.40 difference of the mean change in metabolic syndrome scores after 6 months between arms using a Mann-Whitney test.

  • Change in effectiveness of atorvastatin calcium on the prevention of metabolic syndrome [ Time Frame: At 3 and 6 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Change in Safety and tolerability of atorvastatin calcium [ Time Frame: Adverse Events (AE) at 3 and 6 months ] [ Designated as safety issue: Yes ]
    Safety will be assessed when approx 30 patients (50%) have completed the 3 month assessment based on the frequency and % of adverse events. 5 patients experiencing any non-hematologic, non-androgen deprivation related grade 3 or greater AE would trigger a systematic review of the AE experience. The frequency of AEs will be compared between the placebo and Atorvastatin groups using a Fisher's Exact test. A p-value of 0.20 will be considered significant for the interim assessment.

  • Impact of atorvastatin calcium on mean change in PSA and PSA velocity [ Time Frame: At 3 and 6 months ] [ Designated as safety issue: No ]
  • Optional collection and banking of blood and serum on subjects for future analysis [ Time Frame: Number of samples collected at baseline and then at 3 and 6 months ] [ Designated as safety issue: No ]
    Optional samples collected for future research that will be proposed in future IRB submissions.


Enrollment: 0
Study Start Date: March 2012
Study Completion Date: February 2013
Primary Completion Date: February 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Arm I (placebo)
Patients receive placebo PO QD for 6 months in the absence of disease progression or unacceptable toxicity.
Drug: placebo
Given PO
Other Name: PLCB
Experimental: Arm II (atorvastatin calcium)
Patients receive atorvastatin calcium PO QD for 6 months in the absence of disease progression or unacceptable toxicity.
Drug: atorvastatin calcium
Given PO
Other Names:
  • CI-981
  • Lipitor

Detailed Description:

PRIMARY OBJECTIVES:

I. To evaluate in a pilot study a preliminary estimate of the overall change of metabolic syndrome score in men undergoing or who have undergone androgen-deprivation therapy for treatment or the control of prostate cancer.

II. To assess the effectiveness of Atorvastatin (atorvastatin calcium) on the prevention of metabolic syndrome in men undergoing or who have undergone androgen-deprivation therapy for treatment or the control of prostate cancer.

SECONDARY OBJECTIVES:

I. To document the safety and tolerability of Atorvastatin in this patient population.

II. To assess the impact of Atorvastatin on mean change in prostate specific antigen (PSA) and PSA velocity.

III. The collection and banking of blood and serum on subjects for future analysis that will be proposed in future institutional review board (IRB) submissions.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients receive placebo orally once daily for 6 months in the absence of disease progression or unacceptable toxicity.

ARM II: Patients receive atorvastatin calcium orally once daily for 6 months in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 30 days, and at 6 months thereafter.

  Eligibility

Ages Eligible for Study:   19 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically confirmed prostate cancer, any stage disease allowed Androgen deprivation for treatment or control of prostate cancer including any of the following:

    • Bilateral orchiectomy
    • Luteinizing hormone-releasing hormone (LHRH) agonist therapy (e.g., leuprolide, goserelin, bicalutamide, flutamide, or similar agents) with or without antiandrogen therapy
  • No statin therapy, antihyperlipidemic, lipid-lowering medications, HMG-COA reductase inhibitor, atorvastatin calcium, or LIPITOR ® use
  • Patients must be willing to give written informed consent, and sign an institutionally approved consent form before performance of any study-related procedure not part of normal medical care based on current diagnosis and clinical condition, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care
  • Karnofsky Performance Status >= 70
  • Able to adhere to the study visit schedule and other protocol requirements
  • No serious disease or condition that, in the opinion of the investigator, would compromise the patient's ability to participate in the study
  • Absolute neutrophil count (ANC) >= 1000 cells/mm^3
  • Platelet Count >= 100 mm^3
  • Serum creatinine < 2.0 mg/dL
  • Aspartate aminotransferase (AST), alanine aminotransferase (ALT) < 2 x the upper limits of normal
  • Hepatic alkaline phosphatase < 2 x the upper limits of normal

Exclusion Criteria:

  • Treatment with a cytotoxic chemotherapy or participation in any other studies involving investigational or marketed products, concomitantly within 30 days before Day 1 of study treatment; palliative radiation therapy is allowed
  • Known positive for human immunodeficiency virus (HIV) or infectious hepatitis, type A, B or C or active Hepatitis
  • Known alcohol and/or any other drug abuse
  • History of intolerance or hypersensitivity to statins and known hypersensitivity to atorvastatin
  • Known history of non-low-density lipoprotein (LDL) cholesterol > 150 mg/dL, peripheral artery disease, coronary heart disease, myocardial infarction (MI) or angina, coronary artery disease or diabetes (as should be receiving statin therapy per current standards); in addition, patients with a known history of smoking, hypertension, family history of myocardial events, and non-LDL > 100 mg/dL
  • Any evidence of severe or uncontrolled systemic disease (e.g., unstable or uncompensated respiratory, cardiac, hepatic, or renal disease) as assessed by the investigator
  • Known cerebrovascular accidents within 6 months before Day 1 of study treatment
  • Treatment with drugs not permitted by the study protocol or the likelihood of requiring treatment during the study period with drugs which might interfere with the absorption and evaluation of study drugs during the study protocol
  • Any other clinically significant medical disease or condition laboratory abnormality or psychiatric illness that, in the Investigator's opinion, may interfere with protocol adherence or a subject's ability to give informed consent
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01555632

Sponsors and Collaborators
University of Nebraska
Investigators
Principal Investigator: Jue Wang University of Nebraska
  More Information

No publications provided

Responsible Party: University of Nebraska
ClinicalTrials.gov Identifier: NCT01555632     History of Changes
Other Study ID Numbers: 429-11, NCI-2012-00046, P30CA036727
Study First Received: February 9, 2012
Last Updated: June 17, 2013
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Prostatic Neoplasms
Metabolic Syndrome X
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases
Insulin Resistance
Hyperinsulinism
Glucose Metabolism Disorders
Metabolic Diseases
Androgens
Calcium, Dietary
Atorvastatin
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Pharmacologic Actions
Bone Density Conservation Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Anticholesteremic Agents
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Enzyme Inhibitors
Lipid Regulating Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on April 22, 2014